Exploring Novel Therapeutic Combination Strategies in Kidney Cancer

Commentary
Video

Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.

Eric Jonasch, MD, spoke with CancerNetwork® at the 2025 Kidney Cancer Research Summit about ongoing initiatives from the Kidney Cancer Research Consortium, a program that he leads to facilitate new research efforts in kidney cancer management. He highlighted the structure and mission of the Kidney Cancer Research Consortium as part of an oral presentation at the meeting.

Regarding specific sets of ongoing trials, Jonasch, a professor in the Department of Genitourinary Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, stated that current efforts include combining base immune-modulating agents, such as nivolumab [Opdivo] plus ipilimumab [Yervoy] or cabozantinib [Cabometyx] plus nivolumab, with novel therapeutic agents. For example, investigators of one trial are assessing the efficacy of LAG3 inhibition; another study is combining the investigational radioisotope lutetium-177 (177Lu) girentuximab with a standard immunotherapy tyrosine kinase inhibitor (IO-TKI) backbone. According to Jonash, this set of trials may help provide the field with “better answers for better treatments” in diseases like renal cell carcinoma.

Transcript:

One of the examples of trials, or sets of trials, that is more likely to provide us better answers for better treatments [focus on] our immune-modulating agents. We have a suite of studies where we’re looking at the base immune therapy combinations—for example, ipilimumab plus nivolumab, or cabozantinib plus nivolumab. Then, we’re adding novel agents onto these regimens. For example, we’ve just completed a study with an A2A receptor inhibitor. We’re also now in the midst of doing a study with relatlimab-rmbw, which is the LAG3 inhibitor. We also have another study where we’re using an IO-TKI backbone, and we’re adding lutetium-177 girentuximab, which is another novel agent. Those are 3 examples of studies where we’re trying to improve on existing study platforms to develop better therapy for patients with renal cell carcinoma.

Reference

Jonasch E. Building the infrastructure for discovery: a clinical trial consortium to accelerate kidney cancer research. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA.

Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.
The use of enhanced imaging and adaptive radiotherapy has lessened the burden on patients with cancer receiving radiotherapy as treatment.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Related Content